3.2.2 Ferroptosis and parkinsons disease PD is the second most prevalent NDD, characterized by the degeneration and loss of dopaminergic neurons in the substantia nigra of the midbrain
Consultation Format: Asynchronous (Most Common): Complete detailed questionnaire online Provider reviews within 24-48 hours Responds with questions or approval Can message with questions Live Video/Phone: Scheduled appointment (15-30 minutes) Real-time discussion with provider Ask questions directly Decision made during visit What Provider Assesses: Eligibility for GLP-1 therapy Which medication is best for you Starting dose Contraindications Realistic expectations Commitment to treatment Step 4: Choose Your Medication Decision Framework: Choose Semaglutide If: Want excellent results at lowest cost Need to lose 20-50 pounds Budget is primary concern ($199/month) Have cardiovascular disease Choose Tirzepatide If: Want maximum results Need to lose 50+ pounds Can afford $349/month Want most effective medication Your provider will help you decide based on your goals, health status, and budget
Standard Berberine HCI is also included for maximum effectiveness with enhanced Absorption with BioPerine Akkermansia & Resistant Starch: Our GLP-1 supplement feature Akkermansia muciniphila, a potent probiotic
Oral GLP-1 Formulations and Novel Delivery Systems: With the successful formulation and commercialization of oral semaglutide (Rybelsus), there is now a way to remove barriers to injecting doses of the GLP-1 therapy and thus achieve a more widespread adoption among patients
2025: Novo Nordisk announced positive Phase 3 ESSENCE trial results for semaglutide in early Alzheimer's disease, reporting statistically significant slowing of cognitive and functional decline a breakthrough data package that could establish GLP-1 therapy as a neuroprotective agent and open an addressable market of 6.5 million Alzheimer's patients in the U.S
